Compare Regeneron Pharmaceuticals Inc (REGN) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs T-Mobile Us Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while T-Mobile Us Inc trades at $177.55 (market cap $194.89B). The key difference: T-Mobile Us Inc is far larger — about 2.3× Regeneron Pharmaceuticals Inc's market cap, and T-Mobile Us Inc pays the higher dividend (2.25%). Which is the better fit depends on your goals.
| REGN | TMUS | |
|---|---|---|
Market Cap | $83.43B | $194.89B |
Sector | Health | Media |
52-Week High | $852.03 | $241.67 |
52-Week Low | $555.51 | $167.65 |
Enterprise Value | $78.14B | $311.51B |
Dividend Yield | 0.46% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
T-Mobile US (TMUS) trades at $181.69, showing minimal daily movement (+0.09%) amid a bearish technical signal. The company demonstrates strong fundamentals with $88.3B revenue (2025) and consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 80% buy ratings and a $233.20 consensus target, though technical indicators show near-term resistance at $183. Recent developments include CFO transition planning and institutional accumulation by California State Teachers Retirement System.
TMUS presents a compelling growth story with solid profitability metrics and analyst support, though technical weakness and competitive pressures warrant caution. The stock's 28% upside to consensus target offers potential, but investors must weigh strong cash flow generation against rising debt levels and sector-wide pricing pressures evident in recent broadband repricing trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
